GPC Biotech’s Satraplatin Fails To Meet Survival Endpoint In SPARC Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Next-generation oral platinum chemotherapy remains a Phase II asset worth partnering, CEO Seizinger maintains.
You may also be interested in...
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.
GPC Biotech Merger With Agennix May Have A Billionaire’s Reasons For Success
Key to the deal is investment by German billionaire Dietmar Hopps; GPC, troubled since satraplatin failed to meet trial endpoints, gains Agennix’s NCSLC candidate, talactoferrin.